Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine and Microgynon Interaction in RMS
NCT03745144Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of cladribine in multiple sclerosis (MS) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Zero to Tau at Steady State of Ethinyl Estradiol and Levonorgestrel at Day 14, Maximum Observed Plasma Concentration in Steady State of Ethinyl Estradiol And Levonorgestrel at Day 14 and 5 more. Started Jan 2019; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03745144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745144.